Navigation Links
Thoratec Reports 44 Percent Increase in Third Quarter Revenues
Date:10/30/2008

) for bridge-to-transplantation, which helped generate a 68 percent increase in revenues from our Cardiovascular Division versus a year ago," said Gary F. Burbach, president and chief executive officer of Thoratec. "In addition to experiencing greater implant activity, we also added 17 new HeartMate II centers during the quarter. We have now added a total of 43 new centers, surpassing our goal of adding 40 new centers during the year," he added.

"I am very pleased with our results to date and based on our performance through the first three quarters of the year, we believe we are positioned to have a highly successful 2008. At the same time, we are implementing programs to add new HeartMate II centers and increase activity from referring cardiologists that are designed to lay a foundation for long-term growth," Burbach added.

The company also updated enrollment in the Destination Therapy (DT) arm of its pivotal clinical trial for the HeartMate II. As of October 24, 2008, there were 607 patients enrolled in the DT arm of the trial, including 366 patients in the randomized portion of the study.

FINANCIAL HIGHLIGHTS

Thoratec reported revenues of $80.8 million in the third quarter of 2008 compared with revenues of $56.1 million in the third quarter of 2007. Cardiovascular Division revenues were $57.1 million versus $34.0 million in the same period a year ago. Revenues at ITC were $23.7 million versus $22.0 million a year ago.

GAAP gross margin in the third quarter of 2008 was 60.3 percent versus 57.7 percent a year ago. Non-GAAP gross margin, which excludes SFAS No. 123R expense and is described later in this press release, was 60.8 percent versus 58.5 percent a year ago. The improvement in gross margin reflects primarily the increase in average selling prices associated with U.S. commercial approval of the HeartMate II. This was partially offset by lower margins at ITC primarily related to geographic and product mix, and unfavorable m
'/>"/>

SOURCE Thoratec Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Thoratec Schedules Third Quarter 2008 Conference Call, Webcast
2. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
3. Thoratec Presentation at JP Morgan Conference to be Webcast
4. Thoratec Announces Appointment of Steven H. Collis to Board of Directors
5. Thoratec Presentation at Bear Stearns Conference To Be Webcast
6. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
7. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
8. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
9. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
10. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
11. United Therapeutics Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 Yuma Regional Cancer Center ... therapies brings comprehensive cancer care to Yuma, Arizona. ... Cancer Center has officially opened. A Mayo Clinic ... services such as open, semi-private and private infusion ... Society Resource Center, hematology, rehabilitation center, a pain ...
(Date:7/30/2014)... --  Epic Sciences, Inc. ("Epic"), a private biotech ... and advance the treatment and management of cancer, announced ... as chairman of Epic,s board of directors. Mr. Lucier ... Invitrogen). Mr. Lucier joins Epic,s board of directors to ... analysis platform with special focus on the development of ...
(Date:7/30/2014)... CT (PRWEB) July 30, 2014 Connecticut ... development organization based in East Hartford, Conn., was awarded ... Phase II of a project that will determine the ... in rural north-central Connecticut. USDA Rural Development provided $53,000 ... program for the second phase of the feasibility study ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 LayerBio, ... announces completion of its first round of seed financing ... will enable preliminary efforts to develop a novel sustained-release ... support of our investors and their commitment to this ... of LayerBio. "Ophthalmology is one of many areas in ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3
... Inc., a privately held molecular diagnostics company developing innovative ... announced today the appointment of Peter Blume-Jensen, M.D., Ph.D. ... Metamark with over 20 years of experience in cancer ... Dr. Blume-Jensen was department head at EMD Serono, Inc. ...
... 16 Cord Blood America, Inc . ( ... the umbilical cord blood stem cell preservation company ... stem cells, a biological insurance policy, to families nationwide ... and CEO, was interviewed by analyst Francis Gaskins on ...
... LOUIS, Sept. 15 Sigma-Aldrich Corporation (Nasdaq: SIAL ... Healthcare Conference on Tuesday, September 21st at 12:30 PM ET ... audio broadcast over the Internet available at http://investor.sigmaaldrich.com/ . ... About Sigma-Aldrich: Sigma-Aldrich is ...
Cached Biology Technology:Metamark Genetics, Inc. Announces New Chief Scientific Officer 2Cord Blood America CEO Matthew Schissler Discusses Projects in China, South America, 'Afford-A-Cord,' and Profitability 2
(Date:7/30/2014)... team of biologists, led by Clemson University associate professor ... pest that will pave the way for novel anti-fouling ... for medical and industrial applications. , The team,s findings, ... the last larval stage of barnacles that attaches to ... possibly polymeric material that acts as an underwater heavy-duty ...
(Date:7/30/2014)... 2014 NexID Biometrics , a ... solutions for the biometric authentication industry, has recently ... online authentication with standards for strong authentication. According ... decision to join FIDO Alliance stems from NexID,s ... use. We believe the FIDO Alliance is a ...
(Date:7/30/2014)... how to create colors, nature had already perfected the ... different hues, for example. Now scientists are tapping into ... to make colored plastics. Their paper on using structure ... rather than dyes, to produce color appears in the ... Mortensen, Anders Kristensen and colleagues point out that currently, ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2NexID Biometrics Joins the FIDO Alliance 2
... Medicine have discovered a technique that directly converts skin ... patients with multiple sclerosis, cerebral palsy and other so-called ... in the journal Nature Biotechnology . This ... which provide a vital sheath of insulation that protects ...
... 14, 2013)Stenting reopens completely blocked bowel arteries, preventing ... causes individuals severe pain and leads to excessive ... Society of Interventional Radiology,s 38th Annual Scientific Meeting ... mesenteric arteries saves lives," said Daniel A. Leung, ...
... mechanism that causes a slime to form, making bacteria ... under threat, some bacteria can shield themselves in a ... made up of communities of bacteria held together to ... and sinusitis; in healthcare, biofilms can lead to life ...
Cached Biology News:Ordinary skin cells morphed into functional brain cells 2Stenting blocked bowel arteries saves lives 2Secrets of bacterial slime revealed 2
Recombinant Mouse MMP-9, CF...
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Blue Standard is 3-cyano-7-hydroxycoumarin....
6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE)...
Biology Products: